ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
AstraZeneca PLC

AstraZeneca PLC (AZN)

65,6899
-0,5701
( -0,86% )
Aktualisiert: 18:22:20

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
65,6899
Gebot
65,68
Fragen
65,69
Volumen
1.489.064
65,325 Tagesbereich 66,11
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
66,26
Handelsbeginn
66,11
Letzte Trade
5
@
65.68
Letzter Handelszeitpunkt
18:22:21
Finanzvolumen
US$ 97.691.731
VWAP
65,6061
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
3.100.634.378
Dividendenrendite
2.21%
Kurs-Gewinn-Verhältnis
54,16
Gewinn pro Aktie (EPS)
1,92
Erlöse
45,81B
Nettogewinn
5,96B

Über AstraZeneca PLC

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put s... AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Cambridge, Gbr
Gegründet
-
AstraZeneca PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AZN. The last closing price for AstraZeneca was US$66,26. Over the last year, AstraZeneca shares have traded in a share price range of US$ 0,00 to US$ 0,00.

AstraZeneca currently has 3.100.634.378 shares in issue. The market capitalisation of AstraZeneca is US$205,45 billion. AstraZeneca has a price to earnings ratio (PE ratio) of 54.16.

Option-Flow AstraZeneca (AZN)

Gesamtfluss

Bärisch

Nettoprämie

-451k

Calls / Puts

0,00%

Käuf. / Verkä.

20,00%

OTM / ITM

0,00%

Sweeps

0,00%

AZN Neueste Nachrichten

Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against AstraZeneca PLC (AZN) - February 21, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 30, 2024 NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The...

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the comparator arm First and only PARP inhibitor to improve survival in early breast cancer Updated results from the...

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

First Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Based on TROPION-Lung05 Phase II trial and supported by data from TROPION-Lung01 Phase III trial...

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting CALQUENCE plus venetoclax poised to become first...

IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer

Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit If approved, this will be the...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

AZN - Frequently Asked Questions (FAQ)

What is the current AstraZeneca share price?
The current share price of AstraZeneca is US$ 65,6899
How many AstraZeneca shares are in issue?
AstraZeneca has 3.100.634.378 shares in issue
What is the market cap of AstraZeneca?
The market capitalisation of AstraZeneca is USD 205,45B
What is the 1 year trading range for AstraZeneca share price?
AstraZeneca has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of AstraZeneca?
The price to earnings ratio of AstraZeneca is 54,16
What is the cash to sales ratio of AstraZeneca?
The cash to sales ratio of AstraZeneca is 7,04
What is the reporting currency for AstraZeneca?
AstraZeneca reports financial results in USD
What is the latest annual turnover for AstraZeneca?
The latest annual turnover of AstraZeneca is USD 45,81B
What is the latest annual profit for AstraZeneca?
The latest annual profit of AstraZeneca is USD 5,96B
What is the registered address of AstraZeneca?
The registered address for AstraZeneca is 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA
Which industry sector does AstraZeneca operate in?
AstraZeneca operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
NXUNXU Inc
US$ 1,6699
(586,07%)
421,64M
WATTEnergous Corporation
US$ 1,461
(255,30%)
164,41M
INTZIntrusion Inc
US$ 5,53
(156,02%)
114,5M
HOLOMicroCloud Hologram Inc
US$ 4,52
(88,33%)
99,55M
CYNCYNGN Inc
US$ 1,1699
(86,32%)
60,74M
ABPAbpro Holdings Inc
US$ 2,0501
(-54,34%)
1,39M
TRAWTraws Pharma Inc
US$ 7,825
(-41,69%)
896,28k
LITMSnow Lake Resources Ltd
US$ 1,1168
(-30,20%)
44,58M
LGHLWLion Group Holding Ltd
US$ 0,0052
(-25,71%)
54,82k
BITSGlobal X Blockchain and Bitcoin Stratagy ETF
US$ 66,74
(-24,56%)
8,96k
NXUNXU Inc
US$ 1,6699
(586,07%)
421,64M
VINCVincerx Inc
US$ 0,3519
(81,39%)
296,96M
XTIAXTI Aerospace Inc
US$ 0,0398
(0,76%)
184,49M
WATTEnergous Corporation
US$ 1,461
(255,30%)
164,41M
SMXSMX Security Matters Public Company
US$ 0,58
(64,03%)
132,06M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen